The company’s Chinese investee received CE approval for a nucleic acid diagnostics kit for COVID-19, meaning it can now start selling the device in Europe, currently the epicentre of the coronavirus pandemic. Western countries’ efforts to stem COVID-19 infections have been hampered by a lack of tests.
In Australia overnight the first of 100,000 kits were due to arrive, alleviating the shortage here.
So just imagine all the orders and disturbution deals. Soon FDA approval for American market.
Note: no public company in ASX has achieved anything like this. TBG owns 47 per cent of TBG Biotechnology Xiamen. The kit made by the Chinese company uses RNA (ribonucleic acid) to detect the RDRP, N and E genes of the COVID-19 virus.
